

Effect of Amantadine on Serum Levels of Bilirubine in Native Poultry

¹Khayatnouri Mirhadi, ²Yagoobnegad Alireza and ²Safarmashaei Saeid

¹Department of Pharmacology, Tabriz Branch, Islamic Azad University, Tabriz, Iran

²Veterinary Science Student, Tabriz Branch, Islamic Azad University, Tabriz, Iran

Abstract: Clinical trials have documented that amantadine hydrochloride is effective drug for the prophylaxis and treatment of influenza A virus infection. Nowadays the use of amantadine for treatment of influenza has been increased. The aim of present study was to determine the effect of Amantadine on serum Bilirubine in native poultry. 10 adult hens weighing between 2 and 2.5 kg were used for the study. In first steps one blood sample were taken. In secondary steps amantadine (orally) with dose of 25mg/kg for 4 consecutive week were administrated. Blood samples on days 1, 3, 7, 14, 21 and 28 after administration from every hen were taken and after centrifugation serums for titration of Bilirubine by standards kits were used. Results revealed significance changes in serum levels of Bilirubine on 3, 7, 14, 21, 28 after orally amantadine administration were observed.

Key words: Amantadine • Poultry • Bilirubine

INTRODUCTION

Clinical trials have documented that amantadine hydrochloride [1-5] and its analog rimantadine hydrochloride [2, 5-8] are effective drugs for the prophylaxis and treatment of influenza A virus infection. However, widespread use of amantadine has been limited in part by concern about its side effects. Most studies of amantadine prophylaxis have documented minimal toxicity at a dosage of 200mg/day [3, 4, 9] but the frequency and severity of side effects increase with increasing dosage [3, 10, 11]. Rimantadine has been considered to be better tolerated in humans than amantadine [2], although conflicting results have been reported from studies of their relative toxicities [9]. Amantadine has been used as an antiparkinsonian drug since 1969 [12]. For several years its main indications have been the treatment of early Parkinson's disease (PD) or as adjunct therapy for more advanced PD patients on stable doses of carbidopa/levodopa. Recently, there has been a renewed interest in its use after discovery of its antidyskinetic effects [13, 14]. Study on side effects of amantadine in animals is very low, but in human some of this side effects is consist of severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); aggression; agitation; confusion; depression; fainting; fast or irregular heartbeat; fever; hallucinations; memory loss; mental or mood changes; muscle problems (eg, spasms, uncontrolled movements); paranoid thoughts; personality

changes; seizures; severe or persistent drowsiness or trouble sleeping; shortness of breath; sore throat; swelling of hands, legs, feet, or ankles; thoughts of suicide; trouble urinating; unusual anxiety or irritability; vision changes. Nowadays use of amantadine for treatment of influenza has been increased; of course study on effect of amantadine on serumic level of bilirubine has not been reported therefore the goal of present study was to determine the effect of Amantadine on Serum bilirubine in native poultry.

MATERIALS AND METHODS

A total number of 10 Adult hens weighing between 2 and 2.5 kg were used for the study. They were kept under standard laboratory conditions and were fed with standards feeds and drinking water *ad libitum*. Ethical committee in accordance with animal experimentation and care has approved all animal procedures. In first steps one blood sample from wing vein of every hen were taken. In secondary steps amantadine (orally) with dose of 25 mg/kg for 4 consecutive week were administrated. Blood samples on days 1, 3, 7, 14, 21 and 28 after administration from every hen were taken and after centrifugation, serum samples were used for titration of bilirubine by standards kits. Values were represented as mean±SEM. Data were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's test using statistical package for social sciences (SPSS) version 10. $P < 0.05$ was considered significant.

Table 1: The effect of Amantadine on level of serum Bilirubine (mg/dl) in different days.

Time after administration	0	1	3	7	14	21	28
Level of Serum Bilirubine (mg/dl)	0.33±0.03	0.36±0.007	0.39±0.008	0.42±0.005	0.43±0.004	0.43±0.004	0.43±0.006
		P=0.862	P=0.029	P=0.001	P=0.000	P=0.000	P=0.000

P-value compared with day of 0.

RESULTS AND DISCUSSION

Seral titration of Bilirubine by standards kits were calculated and showed in table 1.

In human, deaths have been reported from overdose with Amantadine. The lowest reported acute lethal dose was 1 gram. Because some patients have attempted suicide by overdosing with Amantadine, prescriptions should be written for the smallest quantity consistent with good patient management. Acute toxicity may be attributable to the anticholinergic effects of Amantadine. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress (including adult respiratory distress syndrome-ARDS) have been reported; renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur [15]. Central nervous system effects that have been reported include insomnia, anxiety, agitation, aggressive behavior, hypertonia, hyperkinesia, ataxia, gait abnormality, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucinations, psychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has also been observed in cases where a drug overdose has occurred. There is no specific antidote for an overdose of Amantadine. However, slowly administered intravenous physostigmine in 1 and 2 mg doses in an adult 2 at 1- to 2-hour intervals and 0.5 mg doses in a child 3 at 5- to 10-minute intervals up to a maximum of 2 mg/hour have been reported to be effective in the control of central nervous system toxicity caused by Amantadine hydrochloride. For acute overdosing, general supportive measures should be employed along with immediate gastric lavage or induction of emesis. Fluids should be forced and if necessary, given intravenously [15]. The pH of the urine has been reported to influence the excretion rate of Amantadine. Since the excretion rate of Amantadine increases rapidly when the urine is acidic, the administration of urine acidifying drugs may increase the elimination of the drug from the body. The blood pressure, pulse, respiration and temperature should be monitored. The patient should be observed for

hyperactivity and convulsions; if required, sedation and anticonvulsant therapy should be administered [15]. The patient should be observed for the possible development of arrhythmias and hypotension; if required, appropriate antiarrhythmic and antihypotensive therapy should be given. Electrocardiographic monitoring may be required after ingestion, since malignant tachyarrhythmias can appear after overdose. Care should be exercised when administering adrenergic agents, such as isoproterenol, to patients with an Amantadine overdose, since the dopaminergic activity of Amantadine has been reported to induce malignant arrhythmias. The blood electrolytes, urine pH and urinary output should be monitored. If there is no record of recent voiding, catheterization should be done. Also in one study has been reported that amantadine was effective in the treatment PD-related symptoms for at least 1 year in 40% of patients [15]. In fact study according to results of present study a significance in sermic levels of bilirubine in 3, 7, 14, 21, 28 after orally amantadine administration were observed.

REFERENCES

- Galbraith, A.W., 1975. Therapeutic trials of amantadine (symmetrel) in general practice. *J. Antimicrob. Chemother.* 1: 81-86.
- Hoffman, C.E., 1980. Amantadine HCl and related compounds, pp: 199-211. In W.A. Carter (ed.), *Selective inhibitors of viral functions*. CRC Press, Cleveland, Ohio.
- Jackson, G.G., E.D. Stanley and R.L. Muldoon, 1976. Prevention and control of influenza by chemoprophylaxis and chemotherapy. Prospects from examination of recent experience. *J. Am. Med. Assoc.*, 235: 2739-2742.
- Monto, A.S., R.A. Gunn, M.G. Bandyk and C.L. King., 1979. Prevention of Russian influenza by amantadine. *J. Am. Med. Assoc.*, 241: 1003-1007.
- Van Voris, L.P., R.F. Betts, F.G. Hayden, W.A. Christma and R.G. Dougls, 1981. Successful treatment of naturally occurring influenza A/USSR/77/H1N1. *J. Am. Med. Assoc.*, 245: 1128-1131.

6. Dawkins, A.T., L.R. Giager, Y. Togo, R.B. Hornick and B.A. Harris, 1968. Studies on induced influenza in man. II. Double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride. *J. Am. Med. Assoc.*, 203: 1095-1099.
7. Rablнович, S., J.T. Baldinin and R. Banniter, 1969. Treatment of influenza: the therapeutic efficacy of rimantadine HCl in naturally occurring influenza A2 outbreak. *Am. J. Med. Sci.*, 257: 328-335.
8. Wingfeld, W.L., D. Pollack and R.R. Grunert, 1969. Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. *N. Engl. J. Med.*, 281: 579-584.
9. Pelnpagh, R.O., F.B. Askdn, W.E. Pirce, E.A. Edwards, D.P. Johmon and G.G. Jackson, 1970. Field studies with amantadine: acceptability and protection. *Ann. N.Y. Acad. Sci.*, 173: 62-73.
10. Jackson, G.G., E.D. Stanley and R.L. Mkldoon, 1967. Chemoprophylaxis of viral respiratory diseases. *Bull. Pan Am. Health Org.*, 147: 595-603.
11. Schwab, R.S., D.C. Poskanzer, A.C. Endland and R.R. Young, 1972. Amantadine in Parkinson's disease-review of more than two years' experience. *J. Am. Med. Assoc.*, 222: 792-795.
12. Schwab, R.S., A.C. England, D.C. Jr, Poskanzer, R.R. Young, 1969. Amantadine in the treatment of Parkinson's disease. *JAMA.*, 208: 1168-1170.
13. Blanchet, P.J., S. Konitsiotis and T.N. Chase, 1998. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. *Mov. Disord.*, 13: 798-802.
14. Verhagen Metman, L., P. Del Dotto, P. Van den Munckhof, J. Fang, *et al.* 1998. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. *Neurol.*, 50: 1323-1326.
15. Carlos Singer, M.D., M.D. Spiridon Papapetropoulos, B.A. Gadith Uzcategui and M.D. Lydia Vela, 2006. The Use of Amantadine HCL in Clinical Practice: A Study of Old and New Indications. *The Journal of Applied Res.*, 6(3): 240-245.